Lavinia Negrea1. 1. Renal Division, Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Abstract
BACKGROUND: The vitamin D system is essential for optimal health in humans. Circulating calcitriol, a key metabolite in maintaining calcium and phosphorus homeostasis, is produced in the kidney. In kidney failure, calcitriol levels progressively decrease, contributing to the development of renal secondary hyperparathyroidism (SHPT). SUMMARY: For years, SHPT had a central role in the disturbed mineral metabolism of renal patients. As calcitriol deficiency contributes to SHPT development, treatment with calcitriol or other compounds able to activate the vitamin D receptor (VDR) was one of the mainstays of therapy for renal patients in the last 40 years. In this review, we discuss how the treatment with VDR activators (VDRA) evolved during this time in the United States, as well as the main factors responsible for these changes. KEY MESSAGES: Management of SHPT with VDRA in renal patients has undergone a few paradigm shifts over the last 40 years. When treating SHPT, the newly developed therapies as well as VDRA need to be carefully considered and used appropriately. Nephrologists need to use an integrated approach that avoids excessive use of VDRA, ensures replenishment of vitamin D stores, and avoids hypercalcemia and hyperphosphatemia.
BACKGROUND: The vitamin D system is essential for optimal health in humans. Circulating calcitriol, a key metabolite in maintaining calcium and phosphorus homeostasis, is produced in the kidney. In kidney failure, calcitriol levels progressively decrease, contributing to the development of renal secondary hyperparathyroidism (SHPT). SUMMARY: For years, SHPT had a central role in the disturbed mineral metabolism of renal patients. As calcitriol deficiency contributes to SHPT development, treatment with calcitriol or other compounds able to activate the vitamin D receptor (VDR) was one of the mainstays of therapy for renal patients in the last 40 years. In this review, we discuss how the treatment with VDR activators (VDRA) evolved during this time in the United States, as well as the main factors responsible for these changes. KEY MESSAGES: Management of SHPT with VDRA in renal patients has undergone a few paradigm shifts over the last 40 years. When treating SHPT, the newly developed therapies as well as VDRA need to be carefully considered and used appropriately. Nephrologists need to use an integrated approach that avoids excessive use of VDRA, ensures replenishment of vitamin D stores, and avoids hypercalcemia and hyperphosphatemia.
Authors: M L Melamed; J A Eustace; L Plantinga; B G Jaar; N E Fink; J Coresh; M J Klag; N R Powe Journal: Kidney Int Date: 2006-05-31 Impact factor: 10.612
Authors: Ming Teng; Myles Wolf; M Norma Ofsthun; J Michael Lazarus; Miguel A Hernán; Carlos A Camargo; Ravi Thadhani Journal: J Am Soc Nephrol Date: 2005-02-23 Impact factor: 10.121
Authors: K Kalantar-Zadeh; N Kuwae; D L Regidor; C P Kovesdy; R D Kilpatrick; C S Shinaberger; C J McAllister; M J Budoff; I B Salusky; J D Kopple Journal: Kidney Int Date: 2006-07-05 Impact factor: 10.612
Authors: Geoffrey A Block; Kevin J Martin; Angel L M de Francisco; Stewart A Turner; Morrell M Avram; Michael G Suranyi; Gavril Hercz; John Cunningham; Ali K Abu-Alfa; Piergiorgio Messa; Daniel W Coyne; Francesco Locatelli; Raphael M Cohen; Pieter Evenepoel; Sharon M Moe; Albert Fournier; Johann Braun; Laura C McCary; Valter J Zani; Kurt A Olson; Tilman B Drüeke; William G Goodman Journal: N Engl J Med Date: 2004-04-08 Impact factor: 91.245
Authors: Deborah G Dobrez; Angelo Mathes; Michael Amdahl; Steven E Marx; Joel Z Melnick; Stuart M Sprague Journal: Nephrol Dial Transplant Date: 2004-03-05 Impact factor: 5.992
Authors: Ming Teng; Myles Wolf; Edmund Lowrie; Norma Ofsthun; J Michael Lazarus; Ravi Thadhani Journal: N Engl J Med Date: 2003-07-31 Impact factor: 91.245
Authors: Francesca Tentori; Justin M Albert; Eric W Young; Margaret J Blayney; Bruce M Robinson; Ronald L Pisoni; Takashi Akiba; Roger N Greenwood; Naoki Kimata; Nathan W Levin; Luis M Piera; Rajiv Saran; Robert A Wolfe; Friedrich K Port Journal: Nephrol Dial Transplant Date: 2008-11-21 Impact factor: 5.992
Authors: Sandro Giannini; Giovanni Passeri; Giovanni Tripepi; Stefania Sella; Maria Fusaro; Gaetano Arcidiacono; Marco Onofrio Torres; Alberto Michielin; Tancredi Prandini; Valeria Baffa; Andrea Aghi; Colin Gerard Egan; Martina Brigo; Martina Zaninotto; Mario Plebani; Roberto Vettor; Paola Fioretto; Maurizio Rossini; Alessandro Vignali; Fabrizio Fabris; Francesco Bertoldo Journal: Nutrients Date: 2021-01-14 Impact factor: 5.717
Authors: Felipe Esdras Lucas Cardoso; Leandro da Cruz Melgaço Dos Santos; Adirlene Pontes de Oliveira Tenório; Matheus Rodrigues Lopes; Romero Henrique de Almeida Barbosa Journal: J Vasc Bras Date: 2020-07-06